Patient demographics, clinical and echocardiographic characteristics
| Demographics and baseline data | ||
| Age (years) | 50 (19), range 16–82 | |
| Male gender | 105 (66%) | |
| Height (cm) | 173 (14) | |
| Weight (kg) | 82±16 | |
| Peak oxygen consumption (mL/kg/min) | 19.0 (11.4) | |
| Per cent predicted peak oxygen consumption | 67 (32) | |
| Hypertension | 14 (9%) | |
| Medication | ||
| Calcium antagonist or β-blocker on day of test | 59 (37%) | |
| Calcium antagonist or β-blocker withheld >48 h pretest | 40 (25%) | |
| NYHA functional class | ||
| 2 | 138 (86%) | |
| 3 | 22 (14%) | |
| Echocardiographic parameters | ||
| Basal septal thickness (mm) | 16±4 | |
| LVOT systolic diameter (mm) | 19±3 | |
| Aortoseptal angle (degrees) | 113±12 (range 79–140) | |
| Left ventricular end diastolic diameter (mm) | 46±6 | |
| Distribution of hypertrophy | ||
| Asymmetric | 146 (91%) | |
| Concentric | 10 (6%) | |
| Apical | 4 (3%) | |
| Rest | Provocation | |
| LVOT gradient (mm Hg) | ||
| Whole cohort | 7 (6) | 28 (69) |
| <30 | 160 (100%) | 81 (51%) |
| 30–49 | – | 19 (12%) |
| 50–69 | – | 12 (8%) |
| ≥70 | – | 48 (29%) |
| SAM | ||
| None | 82 (51%) | 62 (39%) |
| Incomplete | 78 (49%) | 39 (24%) |
| Complete | 0 | 59 (37%) |
| Mitral regurgitation | ||
| None | 19 (12%) | 17 (11%) |
| Mild | 139 (87%) | 120 (75%) |
| Moderate | 2 (1%) | 20 (13%) |
| Severe | 0 | 3 (2%) |
Normally distributed data mean±SD, non-parametric data median (IQR).
LVOT, left ventricular outflow tract; NYHA, New York Heart Association; SAM, systolic anterior motion.